

## **Shionogi Announces Participation in Library-Sharing Program Provided by CAC Croit**

---

**OSAKA, Japan, February 28, 2019** - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereinafter "Shionogi") today announced the conclusion of an agreement on participation in the QualityLead program which is offered by CAC Croit Corporation (Head Office: Tokyo, Japan; President and Chief Executive Officer, Hajimu Kato; hereinafter "CAC Croit") and consignment of the management of compound libraries\* and plate production.

\* Compound library: A group of compounds owned and managed by a pharmaceutical company

Under the QualityLead program, CAC Croit will provide a platform for integrated management of compound libraries from pharmaceutical companies, from library management through to plate production. This will help to reduce compound management costs for the pharmaceutical companies. CAC Croit aims to establish a compound library-sharing platform which can be mutually shared and used by pharmaceutical companies, academia and venture companies in the future. Through this contract, Shionogi consigns compound library management and plate production for HTS\*\* to CAC Croit. Furthermore, Shionogi intends to give positive consideration to the sharing of compound libraries that QualityLead Program aspires to establish in the future.

\*\* HTS (High Throughput Screening): Starting step of the drug discovery process to identify the compound (hit compound) from the compound library with the highest affinity with the target molecule.

Recently, the method of identification of a hit compound has become very diverse in small molecule drug discovery, and accordingly, it has become important to establish a system to manage and utilize compound libraries more flexibly. Shionogi intends to improve the productivity of its research and development by more efficient management of compound libraries through participation in the QualityLead program.

Shionogi has established the vision "Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare." In line with this vision, we will continue to strive to contribute to improving the health and QOL of people around the world through providing innovative new drugs now and in the future.

# Press Release



## **About CAC Croit:**

CAC Croit is a member of the CAC group, which has approximately 20 group companies both in Japan and abroad, and offers an advanced, high quality one-stop service that integrates Contract Research Organization (CRO) and Information Technology (IT) to support rapid and efficient pharmaceutical development.

## **About QualityLead Program:**

The QualityLead program is a platform that CAC Croit provides for integrated management of compound libraries from pharmaceutical companies, from library management through to plate production, for drug discovery research. This helps to reduce compound management costs in the form of large capital investment and maintenance fees for the pharmaceutical companies. By establishing this compound library-sharing platform and offering it to pharmaceutical companies, academia and bio-venture companies, CAC Croit will strengthen industry-industry and industry-government-academia collaboration, hence also enhancing “All Japan” drug discovery systems to help develop innovative Japanese drugs. This platform, as part of the QualityLead program, was selected as one of the Japan Agency for Medical Research and Development’s (AMED) Cyclic Innovation for Clinical Empowerment (CiCLE) programs and implemented with the support of AMED. Please refer to the [website of CAC Croit](#) for further details.

## ***Forward Looking Statement***

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

## **Contacts:**

Corporate Communications, Shionogi & Co., Ltd.  
Telephone: +81-6-6209-7885